Factors associated with discontinuation of treatment for pulmonary arterial hypertension in the United States

被引：0
|
作者：
Farber, Harrison W. [1 ]
Germack, Hayley D. [2 ]
Croteau, Nicole S. [3 ]
Simeone, Jason C. [3 ]
Tang, Fei [3 ]
Paoli, Carly J. [2 ]
Doad, Gurinderpal [4 ]
Panjabi, Sumeet [2 ]
De Marco, Teresa [5 ]
机构：
[1] Tufts Med Ctr, Div Pulm Crit Care & Sleep Med, Boston, MA 02111 USA
[2] Janssen Sci Affairs LLC, Titusville, NJ USA
[3] Cytel, Real World Evidence, Waltham, MA USA
[4] Actelion Pharmaceut, Titusville, NJ USA
[5] Univ Calif San Francisco, Div Cardiol, San Francisco, CA USA
来源：
PULMONARY CIRCULATION | 2024年 / 14卷 / 02期
关键词：
pulmonary arterial hypertension; risk factors; treatment;
D O I：
10.1002/pul2.12326
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Information on factors leading to pulmonary arterial hypertension (PAH) treatment discontinuation is limited. This study analyzed 12,902 new PAH medication users to identify predictors of treatment discontinuation. Treatment by accredited pulmonary hypertension centers and combination therapy with PAH agents from different classes were less likely to result in discontinuation.
引用
收藏
页数：5
相关论文
共 50 条
  • [41] HEALTH OUTCOMES AND COSTS ASSOCIATED WITH ORAL TREPROSTINIL AND SELEXIPAG ONE YEAR INTO TREATMENT: A UNITED STATES CLAIMS DATABASE ANALYSIS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
    Classi, Peter
    Morland, Kellie
    Wu, Benjamin
    Deruiter, Alex
    Lee, Henry
    Stafkey-Mailey, Dana
    Dean, Bonnie
    CHEST, 2021, 160 (04) : 2252A - 2253A
  • [42] Idiopathic Pulmonary Arterial Hypertension and Pulmonary Arterial Hypertension Associated With Congenital Heart Disease in Chinese Children: Similarities, Differences, and Prognostic Factors
    Gu, Li
    Li, Yuan Yuan
    Gu, Ling
    Xie, Liang
    Liu, Han Min
    FRONTIERS IN PEDIATRICS, 2020, 8
  • [43] Pulmonary arterial Hypertension associated with connectivitis
    Sitbon, O.
    REVUE DE MEDECINE INTERNE, 2016, 37 : A22 - A26
  • [44] Pulmonary arterial hypertension and associated conditions
    Ataya, Ali
    Patel, Sheylan
    Cope, Jessica
    Alnuaimat, Hassan
    DM DISEASE-A-MONTH, 2016, 62 (11): : 382 - 405
  • [45] Ibuprofen associated with pulmonary arterial hypertension
    Reactions Weekly, 2016, 1623 (1) : 9 - 9
  • [46] Healthcare Utilization And Direct Costs Among Pulmonary Arterial Hypertension Patients Before And After Treatment Initiation In The United States
    Burger, C. D.
    Ozbay, B.
    Riehle, E.
    Montejano, L. B.
    White, R. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [47] Advances in the diagnosis and treatment of HIV-associated pulmonary arterial hypertension
    Krishnan, Mrinalini
    Barnett, Christopher F.
    EXPERT OPINION ON ORPHAN DRUGS, 2020, 8 (05): : 169 - 177
  • [48] Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease
    Kotlyar, Eugene
    Sy, Raymond
    Keogh, Anne M.
    Kermeen, Fiona
    Macdonald, Peter S.
    Hayward, Christopher S.
    McNeil, Keith D.
    Celermajer, David S.
    CARDIOLOGY IN THE YOUNG, 2006, 16 (03) : 268 - 274
  • [49] Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects
    Sitbon, O.
    Beghetti, M.
    Petit, J.
    Iserin, L.
    Humbert, M.
    Gressin, V.
    Simonneau, G.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2006, 36 : 25 - 31
  • [50] Treatment of Non-Group 1 Pulmonary Hypertension: Results of a Survey of Pulmonary Hypertension Centers in the United States
    Pugh, M. E.
    Hemnes, A. R.
    Newman, J. H.
    Robbins, I. M.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2012, 31 (04): : S211 - S211
12345